Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.570
0.00 (0.00%)
Mar 6, 2026, 8:55 AM EST - Market open
Daré Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | -0.06 | 0.01 | 2.81 | 10 | - | - | Upgrade
|
| Revenue Growth (YoY) | - | -99.65% | -71.92% | - | - | - | Upgrade
|
| Cost of Revenue | 14.3 | 14.31 | 21.64 | 30.14 | 0.1 | 0.08 | Upgrade
|
| Gross Profit | -14.35 | -14.3 | -18.83 | -20.14 | -0.1 | -0.08 | Upgrade
|
| Selling, General & Admin | 9.18 | 9.16 | 11.91 | 11.24 | 8.35 | 6.55 | Upgrade
|
| Research & Development | -6.07 | - | - | - | 30.62 | 20.77 | Upgrade
|
| Operating Expenses | 3.11 | 9.16 | 11.91 | 11.24 | 38.97 | 27.32 | Upgrade
|
| Operating Income | -17.47 | -23.45 | -30.74 | -31.39 | -39.07 | -27.4 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.59 | 19.4 | 0.78 | 0.44 | 0 | 0 | Upgrade
|
| EBT Excluding Unusual Items | -18.06 | -4.05 | -29.96 | -30.95 | -39.07 | -27.4 | Upgrade
|
| Other Unusual Items | - | - | -0.4 | - | 0.37 | - | Upgrade
|
| Pretax Income | -17.46 | -4.05 | -30.16 | -30.95 | -38.7 | -27.4 | Upgrade
|
| Net Income | -17.46 | -4.05 | -30.16 | -30.95 | -38.7 | -27.4 | Upgrade
|
| Preferred Dividends & Other Adjustments | - | - | - | - | - | 0.01 | Upgrade
|
| Net Income to Common | -17.46 | -4.05 | -30.16 | -30.95 | -38.7 | -27.41 | Upgrade
|
| Shares Outstanding (Basic) | 10 | 8 | 7 | 7 | 5 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 10 | 8 | 7 | 7 | 5 | 3 | Upgrade
|
| Shares Change (YoY) | 15.58% | 16.80% | 3.23% | 38.29% | 103.23% | 93.16% | Upgrade
|
| EPS (Basic) | -1.82 | -0.48 | -4.15 | -4.39 | -7.59 | -10.93 | Upgrade
|
| EPS (Diluted) | -1.82 | -0.48 | -4.15 | -4.39 | -7.59 | -10.93 | Upgrade
|
| Free Cash Flow | -6.85 | 4.82 | -39.49 | -18.15 | -28.78 | -25.25 | Upgrade
|
| Free Cash Flow Per Share | -0.71 | 0.57 | -5.43 | -2.58 | -5.65 | -10.07 | Upgrade
|
| Gross Margin | - | - | - | -201.42% | - | - | Upgrade
|
| Operating Margin | - | -239692.20% | -1094.77% | -313.86% | - | - | Upgrade
|
| Profit Margin | - | -41430.90% | -1074.17% | -309.48% | - | - | Upgrade
|
| Free Cash Flow Margin | - | 49276.38% | -1406.26% | -181.52% | - | - | Upgrade
|
| EBITDA | -16.36 | -23.41 | -30.7 | -31.36 | -39.04 | -27.36 | Upgrade
|
| D&A For EBITDA | 1.11 | 0.04 | 0.04 | 0.02 | 0.03 | 0.04 | Upgrade
|
| EBIT | -17.47 | -23.45 | -30.74 | -31.39 | -39.07 | -27.4 | Upgrade
|
| Revenue as Reported | - | 0.01 | 2.81 | 10 | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.